TuHURA Biosciences, Inc.
HURA
Get informed when a big investor buys or sells
+ FollowMarket Cap$124.82M
Close$
Share Statistics
| Market cap | $124.82 Million |
|---|---|
| Enterprise Value | $118.98 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.63 |
| Beta | -0.01 |
| Outstanding Shares | 63,963,513 |
Return
| Return on Equity | -144.00% |
|---|---|
| Return on Assets | -112.42% |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -3.63 |
|---|---|
| PEG | 115.05 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Kintara Therapeutics Inc
22 employees
CEO: Saiid Zarrabian TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mecha...